Preparation method and application of osteoblast targeting engineered cow milk small cell extracellular vesicles

The method of preparing osteoblast-targeted engineered bovine milk extracellular vesicles addresses the inefficiencies of existing technologies by modifying bovine milk vesicles with phospholipid peptides, achieving precise osteogenic effects and effective bone repair.

CN119055683APending Publication Date: 2024-12-03DALIAN MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411243430.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-05
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing methods for preparing osteogenic extracellular vesicles are inefficient, and they often fail to deliver therapeutic agents to target osteoblasts effectively due to poor targeting, low yield, and potential toxicity, making them unsuitable for precise bone repair.

Method used

A method is developed to prepare osteoblast-targeted engineered bovine milk small extracellular vesicles by modifying bovine milk extracellular vesicles with phospholipid polyethylene glycol maleimide bone targeting peptides, enhancing their targeting ability and reducing toxicity.

Benefits of technology

The engineered vesicles achieve precise osteogenic effects with enhanced bone repair capabilities, demonstrating strong availability, low cost, and low toxicity, making them suitable for bone repair applications.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055683A_ABST
    Figure CN119055683A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method and application of osteoblast targeting engineered cow milk small extracellular vesicles. The preparation method comprises the following steps: performing differential ultracentrifugation on fresh skimmed cow milk to obtain cow milk extracellular vesicles; preparing a storage solution of the phospholipid polyethylene glycol maleimide bone targeting peptide with the concentration of 1 mg / mL; mixing the cow milk extracellular vesicles with a bone targeting peptide storage solution to obtain a mixed solution, and incubating the mixed solution overnight; and centrifuging, resuspending and collecting the mixed solution to obtain the osteoblast targeting engineered cow milk small cell extracellular vesicles SDSSD-sEV. According to the invention, cow milk with the advantages of strong availability, low cost and low toxicity is taken as a small extracellular vesicle source, engineering modification is carried out on the small extracellular vesicle source by using phospholipid polyethylene glycol maleimide bone targeting peptide, and a peptide fragment of targeting osteoblasts is combined on the surface of a cow milk small extracellular vesicle membrane; the osteoblast targeting engineered cow milk extracellular vesicles are prepared, the effect of accurately promoting osteogenesis is achieved, then the bone repair effect is enhanced, and the osteoblast targeting engineered cow milk extracellular vesicles have important research significance and application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedical materials, and in particular to a preparation method and application of osteoblast-targeted engineered bovine milk microcellular extracellular vesicles. Background Art

[0002] Extracellular vesicles (EVs) are a group of membrane vesicles with a lipid bilayer structure. They are a subcellular component released by various cells spontaneously or under certain conditions. According to their structure, size, and source, they can be divided into small extracellular vesicles (sEVs), microvesicles (MVs), apoptotic bodies (ABs), and oncobodies. sEVs exist in various eukaryotic cells and biological fluids, including blood, saliva, urine, cerebrospinal fluid, and cell culture medium. They play a key role in processes such as intercellular signaling and cell communication, and are involved in a variety of biological processes.

[0003] sEVs have the advantages of good biocompatibility and low immunogenicity. With the deepening of research, the defects of natural sEVs are gradually exposed. ① Natural sEVs have poor targeting: mature sEVs are excreted by donor cells into the body fluid circulation. During the circulation process, some sEVs are taken up by other cells in the body and cannot reach the area that needs treatment accurately; ② The number of effective natural sEVs is too small: all sEVs produced by cells enter the body fluid circulation, resulting in that not all sEVs taken up by cells have therapeutic effects; ③ The content of loaded molecules cannot reach the therapeutic concentration: sEVs are processed and assembled in donor cells, inheriting the bioactive substances of donor cells, resulting in a low content of therapeutic substances loaded by sEVs. Therefore, researchers began to artificially prepare special sEVs-engineered sEVs to achieve therapeutic purposes.

[0004] Research on engineering and modifying sEVs to make them have targeting functions has been initially applied to many fields, but there are few studies on bone-targeted modification of sEVs. Cui et al. extracted sEVs secreted by human mesenchymal stem cells MSC, and delivered the small interfering fragment si-Shn3 (BT-Exo-siShn3) of human immunodeficiency virus enhanced binding protein to sEVs targeting osteoblasts. The engineering modification of bone-targeted peptides gave BT-Exo-siShn3 the ability to specifically deliver si-RNA to osteoblasts, thereby achieving the purpose of precise treatment of osteoporosis. Luo's study showed that sEVs (STExos) of bone marrow stromal cells can significantly enhance the osteoblast differentiation of bone marrow mesenchymal stem cells (BMSC) in vitro. However, the injection of STExos into an osteoporosis mouse model failed to improve osteoporosis, mainly because STExos mainly accumulated in the liver and lungs, not in the bones. Therefore, they combined the surface of STExos with BMSC-specific aptamers to enhance its bone targeting effect.

[0005] However, the sEVs currently used in research are mostly collected and secreted from specific cells, such as various tumor cells, mesenchymal stem cells from different sources, immature dendritic cells, etc. The donor cell yield is low, the collection cost is high, and it is time-consuming and labor-intensive. sEVs derived from mesenchymal stem cells have also been proven to have certain biological toxicity.

[0006] Therefore, providing a method for preparing engineered sEVs that is highly available, low in cost, low in toxicity, can achieve precise osteogenic effects and is more economical and effective has important research significance and application value in bone repair. Summary of the invention

[0007] The present invention provides a preparation method and application of osteoblast-targeted engineered milk microcellular extracellular vesicles to solve the above problems.

[0008] In order to achieve the above object, the technical solution of the present invention is:

[0009] In one aspect, the present invention provides a method for preparing osteoblast-targeted engineered bovine milk small extracellular vesicles, comprising the following steps:

[0010] S1: Fresh skim milk was used to obtain milk extracellular vesicles by differential ultracentrifugation;

[0011] S2: Prepare a 1 mg / mL stock solution of phospholipid polyethylene glycol maleimide bone targeting peptide;

[0012] S3: mixing the bovine milk extracellular vesicles with the phospholipid polyethylene glycol maleimide bone targeting peptide storage solution, and incubating the obtained mixture overnight;

[0013] S4: Centrifuge, resuspend and collect the mixed solution to obtain osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV.

[0014] Furthermore, the volume ratio of the milk extracellular vesicles to the phospholipid polyethylene glycol maleimide bone targeting peptide storage solution is 9:1.

[0015] Furthermore, the specific steps of S1 include the following steps:

[0016] S11: fresh skim milk is centrifuged at 4°C and 13000g for 0.5h, the middle whey is collected and filtered through a 600-800 mesh filter to obtain a first filtrate;

[0017] S12: centrifuging the first filtrate at 4°C and 100,000 g for 2 h, collecting the middle whey and filtering it sequentially through a vacuum pump with 0.22 μm and 0.45 μm filter membranes to obtain a second filtrate;

[0018] S13: the second filtrate was centrifuged at 4°C and 135000g for 1.5 h, the obtained precipitate was resuspended with PBS, and the resuspended solution was collected and filtered through a 0.22 μm filter membrane to obtain a third filtrate;

[0019] S14: The third filtrate was centrifuged at 4°C, 100,000 g for 2 h, the obtained precipitate was resuspended with 1 mL of PBS, and the suspension was collected to obtain milk extracellular vesicles Milk-sEV, which were stored at -80°C.

[0020] Furthermore, the specific steps of S2 are: weigh 0.001 g of phospholipid polyethylene glycol maleimide bone targeting peptide DSPE-PEG-Mal-Cys-Ser-Asp-Ser-Ser-Asp powder, dissolve it in 1 mL PBS, prepare a storage solution with a concentration of 1 mg / mL, and store it at -80°C.

[0021] Furthermore, the specific steps of centrifuging, resuspending and collecting the mixed solution in S4 are: centrifuging the mixed solution at 4°C, 135,000g for 2 hours, resuspending the precipitate with PBS, and collecting the osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV.

[0022] Another aspect of the present invention provides a method for preparing osteoblast-targeted engineered bovine milk small extracellular vesicles and use of the osteoblast-targeted engineered bovine milk small extracellular vesicles prepared by the method in bone repair.

[0023] The beneficial effects of the present invention are:

[0024] The present invention discloses a method for preparing osteoblast-targeted engineered bovine milk small extracellular vesicles, which uses bovine milk small extracellular vesicles with the advantages of strong availability, low cost and low toxicity as a source, and uses phospholipid polyethylene glycol maleimide bone-targeting peptide to modify it to prepare osteoblast-targeted engineered bovine milk small extracellular vesicles. The method can bind osteoblast-targeted peptides on the membrane surface of the bovine milk small extracellular vesicles through engineering modification of the bovine milk small extracellular vesicles, thereby achieving a precise osteogenesis effect, thereby enhancing its bone repair effect, and has important research significance and application value in bone repair. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0026] Figure 1 Schematic diagram of the preparation process of an osteoblast-targeted engineered bovine milk small extracellular vesicle disclosed in an embodiment of the present invention;

[0027] Figure 2 The results of transmission electron microscopy and marker protein analysis of the osteoblast-targeted engineered bovine milk small extracellular vesicles of the present invention;

[0028] Figure 3 This is the nano-flow analysis result of the osteoblast-targeted engineered bovine milk small extracellular vesicles of the present invention;

[0029] Figure 4 The imaging results of osteoblast-targeted engineered bovine milk minicellular extracellular vesicles in small animals of the present invention are as follows;

[0030] Figure 5 The osteoblast-targeted engineered bovine milk small extracellular vesicles cell targeting results of the present invention;

[0031] Figure 6 The analysis results of the osteoblast-targeted engineered bovine milk small extracellular vesicles of the present invention promoting bone formation;

[0032] Figure 7 These are the analysis results of the osteoblast-targeted engineered bovine milk small extracellular vesicles described in the present invention promoting osteoblast proliferation and differentiation.

[0033] In the figure: 1. bovine milk; 2. bovine milk extracellular vesicle Milk-sEV; 3. osteoblast targeting peptide SDSSD; 4. osteoblast-targeted engineered bovine milk small extracellular vesicle SDSSD-sEV; 5. skull defect model; 6. osteoblasts. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0035] Embodiment 1:

[0036] like Figure 1 The method for preparing osteoblast-targeted engineered milk small extracellular vesicles provided in this embodiment comprises the following steps:

[0037] S1: Fresh skim milk (100 ml milk fat content ≤ 0.5 g) was used to obtain milk extracellular vesicles (Milk-sEV) by differential ultracentrifugation;

[0038] S11: centrifuge 1 L of fresh skim milk at 4°C and 13000 g for 0.5 h, collect the middle whey and filter it through a 600-800 mesh filter to obtain the first filtrate, and remove residual fat, cells and cell debris;

[0039] S12: centrifuging the first filtrate at 4°C and 100,000 g for 2 h, collecting the middle whey and filtering it sequentially through a vacuum pump with 0.22 μm and 0.45 μm filter membranes to obtain a second filtrate;

[0040] S13: the second filtrate was centrifuged at 4°C and 135000g for 1.5 h, the obtained precipitate was resuspended with PBS, and the resuspended solution was collected and filtered through a 0.22 μm filter membrane to obtain a third filtrate;

[0041] S14: The third filtrate was centrifuged at 4°C, 100,000 g for 2 h, the precipitate was resuspended with 1 mL of PBS, the suspension was collected to obtain milk extracellular vesicles Milk-sEV, and stored at -80°C.

[0042] S2: The phospholipid polyethylene glycol maleimide DSPE-PEG2000-Mal and the bone-targeting peptide Ser-Asp-Ser-Ser-Asp were reacted at a molar ratio of 1:1 at room temperature for 24 hours to prepare DSPE-PEG-Mal-Cys-SDSSD, and the mixture was dialyzed with distilled water in a dialysis bag for 24 hours. The dialyzed solution was freeze-dried to obtain the phospholipid polyethylene glycol maleimide bone-targeting peptide DSPE-PEG-Mal-Cys-Ser-Asp-Ser-Ser-Asp powder;

[0043] Weigh 0.001 g of phospholipid polyethylene glycol maleimide bone targeting peptide DSPE-PEG-Mal-Cys-Ser-Asp-Ser-Ser-Asp powder, dissolve it in 1 mL PBS to prepare a storage solution with a concentration of 1 mg / mL (storage solution of osteogenic targeting peptide SDSSD), and store it at -80°C.

[0044] S3: The bovine milk extracellular vesicles and the phospholipid polyethylene glycol maleimide bone targeting peptide storage solution (storage solution of osteogenic targeting peptide SDSSD) are mixed in a volume ratio of 9:1, and the obtained mixed solution is incubated overnight.

[0045] S4: The mixed solution was centrifuged at 4°C, 135,000 g for 2 h, the precipitate was resuspended with PBS, and the osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV were collected.

[0046] Example 2: Identification of osteoblast-targeted engineered milk small extracellular vesicles SDSSD-sEV prepared in Example 1

[0047] The size, structure and shape of milk-derived sEVs (Milk-sEVs) and SDSSD-sEVs were observed by transmission electron microscopy. The protein expression levels of surface markers CD81, CD63, ALIX and microcapsule surface marker CD40 of milk-derived sEVs and SDSSD-sEVs were detected by Western Blot. The results are shown in Table 1. Figure 2 As shown;

[0048] like Figure 2 As shown in (A), milk-derived sEVs (Milk-sEVs) and SDSSD-sEVs are mostly round or oval in shape, with a relatively regular morphology, a typical lipid bilayer structure, and a size between 30-150nm;

[0049] like Figure 2As shown in (B), Western bolt detected that the markers of Milk-sEV and SDSSD-sEV, CD81 (anti-CD81, 1:500, abcam), CD63 (anti-CD63, 1:200, abcam) and Alix (anti-Alix, 1:1,000, Abbexa) were positive, while the microvesicle marker CD40 (anti-CD40, 1:1,000, Bioss) was lowly expressed, indicating that the osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV were successfully prepared.

[0050] Example 3: Nanoflow cytometry analysis of osteoblast-targeted engineered milk small extracellular vesicles SDSSD-sEV prepared in Example 1

[0051] Nanoflow cytometry was used to detect the efficiency of SDSSD modification of Milk-sEV. The results are as follows: Figure 3 As shown, the efficiency of SDSSD modification of Milk-sEV was 83.5%.

[0052] Example 4: Small animal imaging of osteoblast-targeted engineered milk small extracellular vesicles SDSSD-sEV prepared in Example 1

[0053] PKH26 labeled Milk-sEV and SDSSD-sEV, respectively, and then placed into the established skull defect model for small animal imaging; PKH26 labeled Milk-sEV and SDSSD-sEV, respectively, and then injected into the small animal tissues and organs through the tail vein for small animal imaging; the results are shown in Figure 4 As shown ( Figure 4 (B) The sequence numbers ①-⑧ are heart, lung, spleen, liver, kidney, spine, lower limb bones and upper limb bones respectively);

[0054] Figure 4 (A) shows that compared with the Milk-sEV group without targeted modification, SDSSD-sEV still has a stronger fluorescence signal at 48 hours. Figure 4 (B) shows that in tissue and organ imaging, SDSSD-sEV has a stronger fluorescence signal in the bones of the limbs than Milk-sEV, indicating that SDSSD-sEV has stronger osteogenic targeting in vivo.

[0055] Example 5: Cell targeting detection of osteoblast-targeted engineered milk small extracellular vesicles SDSSD-sEV prepared in Example 1

[0056] Osteoblasts (MC3T3-E1) were cultured at a cell density of 1.0×10 5 cells / well, fibroblast (L929) cell density was 1.0×105 cells / well, macrophages (Raw264.7) cell density was 1.5×10 5 cells / well were inoculated in 6-well plates, and incubated with 20 μg / mL SDSSD storage solution (the same preparation method of the storage solution of osteogenic targeting peptide SDSSD in Example 1) for 6 hours before fluorescence staining detection. Figure 5 The results of fluorescence staining are shown. The white arrow points to the green fluorescence, which is SDSSD. It can be seen that it specifically binds to osteoblasts, while no green fluorescence signals are seen in fibroblasts and macrophages, indicating that SDSSD specifically targets osteoblasts.

[0057] Example 6: Effect of osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV prepared in Example 1 on promoting bone formation

[0058] A bone defect model was constructed on both sides of the skull of C57 mice, and then the hydrogel-loaded SDSSD-sEV was placed into the model. Blood and skull tissue specimens of the mice were collected two weeks later. The results were as follows: Figure 6 As shown;

[0059] Figure 6 (A) is the gross observation result of the skull defect model. The gross observation showed that the boundary of the bone defect in the SDSSD-sEV group was unclear compared with other groups, indicating that SDSSD-sEV can promote bone repair. Figure 6 (B) is the result graph of the effect of SDSSD-sEV group on liver function and kidney function of mice (the horizontal axes of the result graph from left to right are different substances acting on osteoblasts MC3T3-E1, and the vertical axes are alanine aminotransferase specific activity, aspartate aminotransferase specific activity, and urea nitrogen concentration, respectively). The serum biochemical analysis (using aspartate aminotransferase (AST / GOT) colorimetric test kit (AST / GOT Activity Assay Kit), alanine aminotransferase (ALT / GPT) colorimetric test kit (ALT / GPT Activity Assay Kit), urea colorimetric test kit (Urea Colorimetric Assay Kit, Elabscience) showed that SDSSD-sEV had no effect on liver and kidney function, indicating that SDSSD-sEV is not systemically toxic.

[0060] Example 7: Effect of osteoblast-targeted engineered milk small extracellular vesicles SDSSD-sEV prepared in Example 1 on osteoblast proliferation

[0061] Osteoblastic MC3T3-E1 cells were seeded in 6-well plates at a cell density of 1.0×10 5cells / well, SDSSD-sEV with a concentration of 0.5 mg / mL was applied to MC3T3-E1 cells, and the MC3T3-E1 cells after culture at different time points were collected. After 7 days of culture, the collected MC3T3-E1 cells were stained with alkaline phosphatase (BCIP / NBT alkaline phosphatase colorimetric kit, beyotime), and after 21 days of culture, alizarin red staining (osteoblast mineralized nodule staining kit, beyotime) was performed. After 7 days of culture, ALP microenzyme labeling (alkaline phosphatase activity assay kit (Alkaline Phosphatase Activity Assay Kit, Elabscience) was performed. At the same time, the control group (no small extracellular vesicles or osteoblast targeting peptide SDSSD were added), the SDSSD group (the osteoblast targeting peptide SDSSD was added), and the Milk-sEV group (the small extracellular vesicles without targeted modification were added) were used as comparisons. The results are shown in the figure. Figure 7 As shown;

[0062] Figure 7 (A) The results of CCK8 detection of MC3T3-E1 cell proliferation in the control group, SDSSD group, Milk-sEV group, and SDSSD-sEV group (the horizontal axis represents different culture times, and the vertical axis represents the absorbance of the collected cell-containing solution at a wavelength of 450 nm); Figure 7 (B) ALP staining to detect cell differentiation; Figure 7 (C) ALP microenzyme labeling method was used to detect cell differentiation (the horizontal axis is the different substances acting on osteoblasts MC3T3-E1, and the vertical axis is the enzyme activity / gram protein); Figure 7 (D) ARS staining was used to detect cell mineralization, *P<0.05. Figure 7 (A)~ Figure 7 (D) The results showed that SDSSD-sEV promoted the osteogenic differentiation and mineralization of MC3T3-E1 more than the control group, SDSSD group, and Milk-sEV group, indicating that the proliferation effect of SDSSD-sEV on osteoblasts was significantly better than that of other groups.

[0063] Matters not covered by the present invention are known technologies.

[0064] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for preparing osteoblast-targeted engineered milk small extracellular vesicles, characterized in that: The following steps are involved: S1: Fresh skim milk was used to obtain milk extracellular vesicles by differential ultracentrifugation; S2: Prepare a 1 mg / mL stock solution of phospholipid polyethylene glycol maleimide bone targeting peptide; S3: mixing the bovine milk extracellular vesicles with the phospholipid polyethylene glycol maleimide bone targeting peptide storage solution, and incubating the obtained mixture overnight; S4: Centrifuge, resuspend and collect the mixed solution to obtain osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV.

2. The method for preparing osteoblast-targeted engineered milk small extracellular vesicles according to claim 1, characterized in that: The volume ratio of the bovine milk extracellular vesicles to the phospholipid polyethylene glycol maleimide bone targeting peptide storage solution is 9:

1.

3. The method for preparing osteoblast-targeted engineered milk small extracellular vesicles according to claim 1, characterized in that: The specific steps of S1 include the following steps: S11: fresh skim milk is centrifuged at 4°C and 13000g for 0.5h, the middle whey is collected and filtered through a 600-800 mesh filter to obtain a first filtrate; S12: centrifuging the first filtrate at 4°C and 100,000 g for 2 h, collecting the middle whey and filtering it sequentially through a vacuum pump with 0.22 μm and 0.45 μm filter membranes to obtain a second filtrate; S13: the second filtrate was centrifuged at 4°C and 135000g for 1.5 h, the obtained precipitate was resuspended with PBS, and the resuspended solution was collected and filtered through a 0.22 μm filter membrane to obtain a third filtrate; S14: The third filtrate was centrifuged at 4°C, 100,000 g for 2 h, the obtained precipitate was resuspended with 1 mL of PBS, and the suspension was collected to obtain milk extracellular vesicles Milk-sEV, which were stored at -80°C.

4. The method for preparing osteoblast-targeted engineered milk small extracellular vesicles according to claim 1, characterized in that: The specific steps of S2 are: weigh 0.001 g of phospholipid polyethylene glycol maleimide bone targeting peptide DSPE-PEG-Mal-Cys-Ser-Asp-Ser-Ser-Asp powder, dissolve it in 1 mL PBS, prepare a storage solution with a concentration of 1 mg / mL, and store it at -80°C.

5. The method for preparing osteoblast-targeted engineered milk small extracellular vesicles according to claim 1, characterized in that: The specific steps of centrifuging, resuspending and collecting the mixed solution in S4 are: centrifuging the mixed solution at 4°C, 135,000g for 2 hours, resuspending the precipitate with PBS, and collecting the osteoblast-targeted engineered bovine milk small extracellular vesicles SDSSD-sEV.

6. Use of the osteoblast-targeted engineered bovine milk small extracellular vesicles prepared by the method for preparing the osteoblast-targeted engineered bovine milk small extracellular vesicles according to claim 1 in bone repair.